In 2024, a team at JCM published a study on using leukocyte-rich platelet-rich plasma (LR‑PRP) for Osgood‑Schlatter treatment, demonstrating improved outcomes in patients with longer disease duration. This highlight growing interest in regenerative medicine approaches offering long-term pain relief
